Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Shares Bought by SRS Capital Advisors Inc.

SRS Capital Advisors Inc. lifted its holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 146.9% during the 4th quarter, HoldingsChannel.com reports. The firm owned 479 shares of the medical equipment provider’s stock after acquiring an additional 285 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Zimmer Biomet were worth $51,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Roman Butler Fullerton & Co. acquired a new position in shares of Zimmer Biomet in the 4th quarter worth approximately $473,000. Geode Capital Management LLC boosted its holdings in shares of Zimmer Biomet by 2.6% in the third quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after buying an additional 125,852 shares during the period. M&T Bank Corp boosted its holdings in shares of Zimmer Biomet by 48.4% in the third quarter. M&T Bank Corp now owns 26,719 shares of the medical equipment provider’s stock worth $2,884,000 after buying an additional 8,709 shares during the period. KLCM Advisors Inc. acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $7,825,000. Finally, Peddock Capital Advisors LLC acquired a new position in shares of Zimmer Biomet in the fourth quarter worth about $654,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Insider Activity

In other news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction that occurred on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now owns 8,768 shares of the company’s stock, valued at $915,379.20. This trade represents a 14.13 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders own 0.95% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Raymond James decreased their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a report on Friday, February 7th. Barclays decreased their target price on shares of Zimmer Biomet from $118.00 to $112.00 and set an “underweight” rating for the company in a report on Monday, February 10th. JMP Securities restated a “market outperform” rating and set a $140.00 price target on shares of Zimmer Biomet in a report on Friday, February 7th. Stifel Nicolaus raised their price target on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday, January 23rd. Finally, Needham & Company LLC restated a “hold” rating on shares of Zimmer Biomet in a report on Friday, February 7th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Price Performance

NYSE ZBH opened at $107.87 on Friday. The company has a quick ratio of 0.99, a current ratio of 1.91 and a debt-to-equity ratio of 0.43. The stock has a market capitalization of $21.47 billion, a PE ratio of 24.24, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a 50 day moving average price of $105.55 and a two-hundred day moving average price of $107.22. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last released its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 EPS for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the business earned $2.20 EPS. As a group, equities analysts predict that Zimmer Biomet Holdings, Inc. will post 8.22 earnings per share for the current fiscal year.

Zimmer Biomet Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.89%. The ex-dividend date is Monday, March 31st. Zimmer Biomet’s dividend payout ratio is 21.57%.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.